Astatine-211 labeling of insulin: Synthesis and preliminary evaluation in vivo and in vitro
Astatine-211 labeling of insulin: Synthesis and preliminary evaluation in vivo and in vitro
复制标题
DOI:
10.1007/s10967-006-6781-8
复制
发表时间:
2007-02
影响因子:
1.6
通讯作者:
Ning Liu;Yuanyou Yang;L. Zan;J. Liao;Jiannan Jin
中科院分区:
文献类型:
--
作者:
Ning Liu;Yuanyou Yang;L. Zan;J. Liao;Jiannan Jin
A first attempt to label insulin, a small protein with significant affinity to tumors with the α-emitter211At was performed by an indirect method using N-succinimidyl 5-(tributylstannyl)-3-pyridinecarboxylate (SPC) as a bi-functional linker, and the stability of the conjugated insulin (211At-insulin) was evaluated in vitro and in vivo. SPC was synthesized by using 5-bromonicotinic acid as the starting material. With this bi-functional linker, insulin was conjugated with211At in a labeling yield of 30–40%, with radiochemical purity of more than 98%. After 24 hours at room temperature, the radiochemical purity was still more than 95%, implying that211At-insulin is fairly stable in vitro. Biodistribution of211At-insulin was investigated in NIH strain mice.211At accumulated rapidly in the liver post injection, with the maximum uptake of 4.29%I.D/g at 30 minutes, and was mainly excreted by kidney. More importantly,211At-insulin uptake in some key organs or tissues, especially in thyriod, stomach, lung and spleen, was much less than that of free astatide (211At−). This result indicated that211At-insulin has considerable stability in vivo as well as in vitro.